Raw data_MRI relaxivities_Chitosan-Mn_Short-term stability studies

Mn(II)-tagged biopolymer formulations enhanced the longitudinal relaxivity (r₁) compared with free MnCl₂ and with clinically used Gadoteridol® serving as a positive control. AD-DOTA-Mn(II) exhibited the highest relaxivity (r₁ = 21.8 mM⁻¹s⁻¹), outperforming CMD-DOTA-Mn(II) (r₁ = 12.1 mM⁻¹s⁻¹) and CH-DOTA-Mn(II) (r₁ = 10.1 mM⁻¹s⁻¹) using a 9.4 T MR scanner.
In this results file, the relaxivities r1 and r2 of the lead compound, chitosan-DOTA-Mn(II) (CH-DOTA-Mn(II), are reported.Plots of relaxation rates (R1/2, [1/s]) to concentration [mM] curves for CH-DOTA-Mn(II) are shown. A steep increase of the relaxation rates R1 and R2 with r1= 10.1 mM⁻¹s⁻¹ and r2= 42.3 mM⁻¹s⁻¹, respectively for CH-DOTA-Mn(II) at 9.4 T was observed.

相较于游离氯化锰（MnCl₂）以及作为阳性对照的临床用钆特醇（Gadoteridol®），锰(II)标记的生物聚合物制剂可提升纵向弛豫率（longitudinal relaxivity, r₁）。在9.4T磁共振扫描仪（9.4 T MR scanner）下进行测试时，AD-DOTA-Mn(II)展现出最高的纵向弛豫率（r₁=21.8 mM⁻¹s⁻¹），其性能优于CMD-DOTA-Mn(II)（r₁=12.1 mM⁻¹s⁻¹）与CH-DOTA-Mn(II)（r₁=10.1 mM⁻¹s⁻¹）。
本结果文件报告了先导化合物壳聚糖-DOTA-锰(II)（CH-DOTA-Mn(II)）的弛豫率r₁与r₂。本文展示了CH-DOTA-Mn(II)的弛豫速率（R₁、R₂，单位为s⁻¹）随浓度（单位为mM）变化的关系曲线。在9.4T场强下，观测到CH-DOTA-Mn(II)的弛豫速率R₁与R₂随浓度急剧升高，对应数值分别为r₁=10.1 mM⁻¹s⁻¹与r₂=42.3 mM⁻¹s⁻¹。